Medical Oncology最新文献_第9页

Evaluation of the anticancer effects of hydroxycinnamic acid isomers on breast cancer stem cells. 羟基肉桂酸异构体对乳腺癌干细胞抗癌作用的评价。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-11 DOI: 10.1007/s12032-025-02618-3

Tülin Burhanoğlu, Zehra Seda Halbutoğulları, Gulseren Turhal, Asuman Demiroglu-Zergeroglu

{"title":"Evaluation of the anticancer effects of hydroxycinnamic acid isomers on breast cancer stem cells.","authors":"Tülin Burhanoğlu, Zehra Seda Halbutoğulları, Gulseren Turhal, Asuman Demiroglu-Zergeroglu","doi":"10.1007/s12032-025-02618-3","DOIUrl":"10.1007/s12032-025-02618-3","url":null,"abstract":"Research on breast cancer stem cells (BCSCs) is crucial for improving our understanding of their roles in tumor resistance, metastasis, and relapse. This study investigated the anti-cancer effects of two isomers of hydroxycinnamic acids (HCA): para-coumaric acid (PCA) and ortho-coumaric acid (OCA) on breast cancer stem cells (BCSCs). The isolated and characterized stem cells contained CD44 + /CD24 surface markers, exhibited high levels of aldehyde dehydrogenase activity, and were able to form mammospheres. The evaluation of HCAs on stem cell proliferation, cell cycle, and apoptosis was conducted by comparing them with MCF-7, the luminal breast cancer cell line. The viability and immunoblot analyses demonstrated that HCA applications resulted in a dose-dependent decrease in the number of viable cells and inhibited phosphorylation of Extracellular regulated kinases 1/2 (ERK1/2). These findings were supported by the detection of suppressed colony formation and delayed wound-healing in HCA-exposed cells. E-cadherin expression increased in OCA-treated cells. Additionally, the arrest of G1/S phase progression and the downregulation of Cyclin D1 expression exhibited that OCA and PCA-induced cytostatic effects in BSCS cells. After treatment, the increased Annexin-V/7-AAD staining, along with elevated expression of caspase-3/7 and a decreased Bcl-2/Bax ratio, indicated apoptosis mediated by the activation of Janus kinase (JNK) and p38 Mitogen-activated kinase (p38 MAPK). In conclusion, both OCA and PCA exhibit anti-carcinogenic potential on BCSCs; However, OCA has a stronger effect and is becoming a promising candidate for further research.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"73"},"PeriodicalIF":2.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ethical and academic dilemmas in authorship of clinical research publications: a medical oncologist's perspective. 临床研究出版物作者身份的伦理和学术困境：医学肿瘤学家的观点。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-11 DOI: 10.1007/s12032-025-02617-4

Ozgur Tanriverdi

引用次数: 0

Gefitinib induces apoptosis in Caco-2 cells via ER stress-mediated mitochondrial pathways and the IRE1α/JNK/p38 MAPK signaling axis. 吉非替尼通过内质网应激介导的线粒体途径和IRE1α/JNK/p38 MAPK信号轴诱导cco -2细胞凋亡。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-10 DOI: 10.1007/s12032-025-02622-7

Caiyuan Yu, Jinhui Sun, Xinyi Lai, Zhiming Tan, Yang Wang, Haiyan Du, Zhaobin Pan, Tingyu Chen, Ziping Yang, Shicai Ye, Juanhua Quan, Yu Zhou

{"title":"Gefitinib induces apoptosis in Caco-2 cells via ER stress-mediated mitochondrial pathways and the IRE1α/JNK/p38 MAPK signaling axis.","authors":"Caiyuan Yu, Jinhui Sun, Xinyi Lai, Zhiming Tan, Yang Wang, Haiyan Du, Zhaobin Pan, Tingyu Chen, Ziping Yang, Shicai Ye, Juanhua Quan, Yu Zhou","doi":"10.1007/s12032-025-02622-7","DOIUrl":"10.1007/s12032-025-02622-7","url":null,"abstract":"Gefitinib, a selective EGFR-tyrosine kinase inhibitor, exhibits potent cytotoxic effects on colorectal cancer cells, though its precise mechanisms are not fully understood. In this study, we demonstrated that gefitinib induces a dose-dependent cytotoxic response in Caco-2 cells, characterized by disrupted microtubule networks, impaired migration, and reduced viability. Gefitinib triggered apoptosis, as indicated by increased levels of cleaved caspase-3, PARP, and elevated late apoptosis rates. Mechanistically, gefitinib-induced endoplasmic reticulum (ER) stress, marked by the upregulation of IRE1α, CHOP, and ATF4. ER stress inhibition by 4-PBA significantly reduced apoptosis and restored mitochondrial membrane potential (MMP). Additionally, gefitinib-induced apoptosis was mediated through the mitochondrial pathway, reflected by the modulation of Bcl-2 family proteins, including the upregulation of Bax and Bim. Inhibition of the IRE1α-mediated JNK/p38 MAPK pathway further mitigated gefitinib-induced apoptosis and restored MMP. These findings highlight the critical role of ER stress and the IRE1α-JNK/p38 MAPK axis in gefitinib-induced mitochondrial apoptosis, offering potential therapeutic targets for colorectal cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"71"},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advancements in nanoparticles for cancer treatment. 纳米颗粒在癌症治疗中的最新进展。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-10 DOI: 10.1007/s12032-025-02609-4

Dinesh Kumar Sharma

{"title":"Recent advancements in nanoparticles for cancer treatment.","authors":"Dinesh Kumar Sharma","doi":"10.1007/s12032-025-02609-4","DOIUrl":"10.1007/s12032-025-02609-4","url":null,"abstract":"Nanotechnology is a significant factor that has assisted researchers in overcoming medications' permeability and retention effects. This article discusses how different nanoparticles, such as metallic nanoparticles, carbon nanotubes (CNTs), and extracellular vesicles (EVs), are transforming cancer treatments and diagnosis. While CNTs provide photothermal qualities that enable synergistic effects when paired with chemotherapy, EVs provide biocompatibility and immune evasion, enabling effective drug transport. Because of their special optical and magnetic characteristics, metallic nanoparticles are essential for imaging and targeted medication administration. When compared to traditional treatments, these nanoparticles improve bioavailability, decrease systemic toxicity, and increase therapeutic efficacy. Despite increased investigations, the number of licensed nano-drugs has remained relatively high. More investigation is required into targeted drug delivery using nanocarriers to minimize the shielding impact of the protein corona, increase permeability and retention effects, and reduce toxicity to improve clinical translation. This study focuses on novel approaches and state-of-the-art cancer therapies using nanoparticles that target different cancer cells. It also emphasized the advantages of nanoparticle-based cancer therapies over conventional ones, their difficulties, and future promises.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"72"},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chylothorax in thoracic oncology: diagnostic challenges and management strategies. 胸部肿瘤学乳糜胸：诊断挑战和管理策略。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-08 DOI: 10.1007/s12032-025-02620-9

Leonardo Duranti, Luca Tavecchio, Luigi Rolli, Clarissa Uslenghi, Piergiorgio Solli

{"title":"Chylothorax in thoracic oncology: diagnostic challenges and management strategies.","authors":"Leonardo Duranti, Luca Tavecchio, Luigi Rolli, Clarissa Uslenghi, Piergiorgio Solli","doi":"10.1007/s12032-025-02620-9","DOIUrl":"10.1007/s12032-025-02620-9","url":null,"abstract":"Chylothorax is a distinctive form of pleural effusion characterized by the accumulation of chyle within the pleural space. We conducted an analysis of published evidence concerning oncological chylothorax, encompassing complications following thoracic surgery or spontaneous occurrences directly linked to thoracic malignancies. Diagnosis can be established based on clinical features of the pleural effusion and through analysis of pleural fluid. The presence of chylomicrons, measured by lipoprotein electrophoresis, triglyceride levels, and cholesterol content are indicative factors. In cases of spontaneous chylothorax, the identification of pleural effusion on CT scans showing suspicious oncological masses, such as lymphomas, prompts pleural drainage for confirmation of chylothorax. Conversely, post-surgical chylothorax diagnoses are immediate due to the pre-existing pleural drainage. In our last 10 years of experience, we have had only 18 cases of chylothorax: 28% underwent successful redo-surgery and 72% were conservatively treated. All the patients recovered well, and none experienced life-threatening situations. Conservative approaches involve hypo/alipidic diets, total parenteral nutrition, and pharmacological interventions. In persistent and challenging cases of chylothorax where drainage output is excessive, redo-surgery is recommended.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"70"},"PeriodicalIF":2.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions. 吲哚酚在肿瘤治疗中的作用：机制、临床应用及未来发展方向。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-08 DOI: 10.1007/s12032-025-02615-6

Ndapewoshali F Shafombabi, Michael Knott, Petrina Kapewangolo, Javad Sharifi-Rad, Daniela Calina

{"title":"Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions.","authors":"Ndapewoshali F Shafombabi, Michael Knott, Petrina Kapewangolo, Javad Sharifi-Rad, Daniela Calina","doi":"10.1007/s12032-025-02615-6","DOIUrl":"10.1007/s12032-025-02615-6","url":null,"abstract":"Ingenol mebutate (IM), a diterpene ester derived from Euphorbia species, has demonstrated promising anticancer properties through direct cytotoxicity and immune modulation. Despite initial clinical success, its therapeutic use has been curtailed due to safety concerns, including potential links to increased skin cancer risk. This review evaluates the mechanisms of action, preclinical and clinical efficacy, safety, and limitations of IM as an anticancer agent, identifying areas for further development. A comprehensive literature review was performed using Google Scholar to identify English-language articles published from 2010 to 2023. Keywords included \"Ingenol mebutate,\" \"PEP005,\" and \"cancer therapy.\" Articles focusing on IM's pharmacological properties, therapeutic mechanisms, clinical studies, and safety profile were included. IM exerts anticancer effects through dual mechanisms: mitochondrial dysfunction leading to necrosis and immune-mediated cytotoxicity via protein kinase C activation. Preclinical studies show efficacy against pancreatic, colorectal, and epithelial cancers and clinical studies have reported success in treating actinic keratosis and nonmelanoma skin cancers. Challenges include intense local skin reactions and safety concerns, particularly its potential association with increased skin malignancy risk. IM represents a promising therapeutic agent due to its rapid and potent anticancer effects. However, optimizing its safety profile and exploring advanced delivery methods are critical to expanding its clinical applications. Further studies are required to establish its long-term efficacy and potential for broader use in oncology.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"69"},"PeriodicalIF":2.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: The function of Cav-1 in MDA-MB-231 breast cancer cell migration and invasion induced by ectopic ATP5B. 注：Cav-1在异位ATP5B诱导的MDA-MB-231乳腺癌细胞迁移和侵袭中的作用。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-08 DOI: 10.1007/s12032-025-02623-6

Xinjie Dong, Yilei Li, Wei Li, Wenzhe Kang, Rong Tang, Wenyi Wu, Ziyi Xing, Lijuan Zhou

引用次数: 0

Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: advancing precision oncology. 药物基因组学对mdr1相关癌症耐药和创新给药方法的影响：推进精准肿瘤学。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-06 DOI: 10.1007/s12032-025-02611-w

Arun Radhakrishnan, Nikhitha K Shanmukhan, Linda Christabel Samuel

{"title":"Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: advancing precision oncology.","authors":"Arun Radhakrishnan, Nikhitha K Shanmukhan, Linda Christabel Samuel","doi":"10.1007/s12032-025-02611-w","DOIUrl":"10.1007/s12032-025-02611-w","url":null,"abstract":"Currently, there is a growing concern surrounding the treatment of cancer, a formidable disease. Pharmacogenomics and personalized medicine have emerged as significant areas of interest in cancer management. The efficacy of many cancer drugs is hindered by resistance mechanisms, particularly P-glycoprotein (P-gp) efflux, leading to reduced therapeutic outcomes. Efforts have intensified to inhibit P-gp efflux, thereby enhancing the effectiveness of resistant drugs. P-gp, a member of the ATP-binding cassette (ABC) superfamily, specifically the multidrug resistance (MDR)/transporter associated with antigen processing (TAP) sub-family B, member 1, utilizes energy derived from ATP hydrolysis to drive efflux. This review focuses on genetic polymorphisms associated with P-gp efflux and explores various novel pharmaceutical strategies to address this challenge. These strategies encompass SEDDS/SNEDDS, liposomes, immunoliposomes, solid lipid nanoparticles, lipid core nanocapsules, microemulsions, dendrimers, hydrogels, polymer-drug conjugates, and polymeric nanoparticles. The article aims to elucidate the interplay between pharmacogenomics, P-gp-mediated drug resistance in cancer, and formulation strategies to improve cancer therapy by tailoring formulations to genetically susceptible patients.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"67"},"PeriodicalIF":2.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DNA repair in cancers: why is there an alternative? 癌症中的DNA修复：为什么有另一种选择？

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-05 DOI: 10.1007/s12032-024-02581-5

Mrityunjay Tyagi

引用次数: 0

A comparative analysis of gallstones from gallbladder cancer patients and cholelithiasis patients unveiling the association between gallstones and gallbladder cancer. 胆囊癌患者与胆石症患者胆结石的比较分析揭示了胆结石与胆囊癌的关系。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-04 DOI: 10.1007/s12032-025-02614-7

Bhavna Sharma, Ratnakar Shukla, Anand Nagar, Nishith Ekka, Vinay Kumar Kapoor, Anu Behari, Shubha Rani Sharma

{"title":"A comparative analysis of gallstones from gallbladder cancer patients and cholelithiasis patients unveiling the association between gallstones and gallbladder cancer.","authors":"Bhavna Sharma, Ratnakar Shukla, Anand Nagar, Nishith Ekka, Vinay Kumar Kapoor, Anu Behari, Shubha Rani Sharma","doi":"10.1007/s12032-025-02614-7","DOIUrl":"10.1007/s12032-025-02614-7","url":null,"abstract":"Gallstones (GS) are one of the most common gastrointestinal diseases. Till date medical cure for gallstones is not available. Unlike kidney stones, GS need cholecystectomy, i.e. surgical removal of the gallbladder (GB). GS are asymptomatic in most of the cases. They are the cause of GB inflammation that is chronic cholecystitis. GS have been supposed to be an important risk factor for causing gallbladder cancer (GBC). But the exact relationship between GS and GBC is not clear till date. In this study, we have compared the gallstones from cholelithiasis patients with those from patients with GBC. The size, volume and weight of these GS were comparatively analyzed. We have performed compositional as well as heavy metal analysis of the GS for both groups of patients by FTIR, FESEM and ICP-MS. The size and volume of gallstones from GBC patients was found to be on the higher side. We found that the GS from GBC patients were only of cholesterol type while those from cholelithiasis patients were mixed and pigment type. Heavy metals such as As, Pb, Fe were detected in higher concentration in GS from GBC patients. Thus, heavy metals detected in the gallstones could be regarded as the contributing factors to GBC. Further the mechanism of initiation of cancer by heavy metals in presence of cholesterol GS needs to be studied, so that novel strategies can be developed for the prevention of GBC.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"65"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0